Fu Tong, Chen Yuqing, Wang Hao, He Linlin, Zhang Jian, Zhou Yongping, Duan Xuchu, Zhang Xu
Department of Hepatobiliary Surgery, Wuxi No.2 People's Hospital, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.
Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong University, Nantong, China.
Hum Vaccin Immunother. 2025 Dec;21(1):2538330. doi: 10.1080/21645515.2025.2538330. Epub 2025 Jul 24.
Pancreatic cancer is a highly malignant tumor with poor prognosis and limited treatments. Immunotherapy shows promise in improving outcomes, but bibliometric analyses in this field are scarce. Our work reveals emerging trends, identifies research gaps, and highlights shifts in focus, offering valuable guidance for future research of immunotherapy and clinical practice. Pancreatic cancer immunotherapy bibliometric analyses were performed utilizing tools such as CiteSpace, VOSviewer, and RStudio, with a focus on the temporal and spatial distribution, prominent authors, research themes, keywords, and citation networks. The analysis reveals a significant increase in research activity on pancreatic cancer immunotherapy over the past decade, with hotspots including ICIs, CAR-T therapy, novel biomarkers, targeted therapies, the tumor microenvironment, and personalized treatment strategies. This study systematically reviews pancreatic cancer immunotherapy research progress from 1991 to 2024, highlighting key hotspots and trends. Future efforts should focus on ICIs, CAR-T therapy, and combination strategies, to enhance outcomes and extend patient survival.
胰腺癌是一种预后较差且治疗手段有限的高度恶性肿瘤。免疫疗法在改善治疗结果方面显示出前景，但该领域的文献计量分析却很匮乏。我们的研究揭示了新出现的趋势，找出了研究差距，并突出了重点的转变，为免疫疗法的未来研究和临床实践提供了有价值的指导。利用CiteSpace、VOSviewer和RStudio等工具对胰腺癌免疫疗法进行了文献计量分析，重点关注时间和空间分布、杰出作者、研究主题、关键词和引文网络。分析显示，在过去十年中，胰腺癌免疫疗法的研究活动显著增加，热点包括免疫检查点抑制剂（ICIs）、嵌合抗原受体T细胞（CAR-T）疗法、新型生物标志物、靶向疗法、肿瘤微环境和个性化治疗策略。本研究系统回顾了1991年至2024年胰腺癌免疫疗法的研究进展，突出了关键热点和趋势。未来的研究应聚焦于免疫检查点抑制剂、CAR-T疗法和联合策略，以提高治疗效果并延长患者生存期。
